Call (408) 747-0185 or Contact us

DARPP-32 (Phospho-Thr75) Antibody

Catalog No : A0007
  • Applications
    WB, IHC, ELISA
  • Reactivity
    Human, Mouse, Rat
  • Application Dilutions
    WB: 1:500~1:1000 IHC: 1:50~1:100 ELISA: 1:40000
  • Size
    50ul
  • Price
    $175.00
Details
  • Product Name
    DARPP-32 (Phospho-Thr75) Antibody
  • Catalog No
    A0007
  • Storage/Stability
    Stable at -20°C for at least 1 year.
  • Applications
    WB, IHC, ELISA
  • Clonality
    Polyclonal
  • Source
    Rabbit
  • Reactivity
    Human, Mouse, Rat
  • Application Dilutions
    WB: 1:500~1:1000 IHC: 1:50~1:100 ELISA: 1:40000
  • Database Links
    Gene ID: 84152, Swiss-Prot #: Q9UD71, OMIM #: 604399, Unigene #: Hs.286192
  • Image 1
    Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using DARPP-32 (Phospho-Thr75) Antibody. The picture on the right is blocked with the phospho peptide.
  • Immunogen
    The antiserum was produced against synthesized peptide derived from human DARPP-32 around the phosphorylation site of Thr75.
  • Immunogen Range
    41-90
  • Modification Sites
    H: T75 M: T75 R: T75
  • MW
    22 kDa
  • NCBI Gene Symbol
    PPP1R1B
  • Physical Form
    Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Purification
    The antibody was purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
  • Specificity
    DARPP-32 (Phospho-Thr75) Antibody detects endogenous levels of DARPP-32 only when phosphorylated at Thr75.
  • Synonyms
    Dopamine- and cAMP-regulated neuronal phosphoprotein, IPPD, Neuronal phosphoprotein DARPP-32, PPP1R1B
  • Target Modification
    Phospho
Application Images
Image 1 Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using DARPP-32 (Phospho-Thr75) Antibody. The picture on the right is blocked with the phospho peptide.
Image 2 Western blot analysis of lysates from COS7 cells treated with Forskolin 40nM 30', using DARPP-32 (Phospho-Thr75) Antibody. The lane on the right is blocked with the phospho peptide.
  • Xiang, F., Neal, P.: Efficient MCMC for temporal epidemics via parameter reduction. Comput. Stat. Data Anal.
  • Xiang, F., Neal, P.: Efficient MCMC for temporal epidemics via parameter reduction. Comput. Stat. Data Anal.
  • Xiang, F., Neal, P.: Efficient MCMC for temporal epidemics via parameter reduction. Comput. Stat. Data Anal.
  • Xiang, F., Neal, P.: Efficient MCMC for temporal epidemics via parameter reduction. Comput. Stat. Data Anal.
  • Xiang, F., Neal, P.: Efficient MCMC for temporal epidemics via parameter reduction. Comput. Stat. Data Anal.
For the process of attaching edges to nodes, it is straightforward to compute the likelihood using (2). However, because of the nature of weighted sampling without replacement, we have to, for each i, calculate the probability conditi onal on each of the Xi!Xi! permutations of the selected nodes and then aver age over all Xi!Xi! probabilities to arrive at the likelihood. As calculating the exact likelihood in this way is not computationally feasible because the factorial grows faster than the exponential function, we approximate the likelihood based on one permutation of weighted sampling without replacement instead. The contribution by the new edges brought by node i is
Get resources and offers direct to your inbox Sign up